-
METTL14–lncRNA Axis Modulates Inflammation in Ulcerative Col
2026-04-22
This study reveals how METTL14-mediated m6A modification of the lncRNA DHRS4-AS1 regulates inflammation in ulcerative colitis (UC), establishing a novel mechanism involving the DHRS4-AS1/miR-206/A3AR axis. These findings position epitranscriptomic regulators as promising therapeutic targets in inflammatory bowel disease research.
-
RCN2 Drives ESCC Metastasis and Cisplatin Resistance via PI3
2026-04-22
This study uncovers a mechanistic role for RCN2 in promoting metastasis and cisplatin resistance in esophageal squamous cell carcinoma (ESCC) via UBR5-mediated degradation of PPP2CA, activating the PI3K-AKT pathway. These findings highlight RCN2 as a promising therapeutic target and inform future strategies to overcome drug resistance in ESCC.
-
Phenothiazines Induce ROS and Autophagy to Boost Macrophage
2026-04-21
The referenced study demonstrates that phenothiazines, including promethazine hydrochloride, enhance macrophage antibacterial activity by inducing reactive oxygen species (ROS) production and autophagy. These findings illuminate a host-targeted approach for combating intracellular pathogens and suggest promising directions for inflammation and immune metabolism research.
-
ATRX-Deficient Glioma Cells: Enhanced Sensitivity to RTK Inh
2026-04-21
This study demonstrates that ATRX-deficient high-grade glioma cells exhibit heightened sensitivity to receptor tyrosine kinase (RTK) and PDGFR inhibitors, and that combining these drugs with Temozolomide markedly increases cytotoxicity. These findings suggest stratifying glioma therapies by ATRX mutation status and refining clinical trial analyses accordingly.
-
P2Y11 Antagonist NF 340: Advancing GPCR Signaling Research
2026-04-20
NF 340 is a potent, selective P2Y11 antagonist enabling researchers to precisely dissect GPCR signaling in immunology and cancer invasion models. Its reproducibility and high specificity, uniquely validated in breast cancer invasiveness workflows, make it a cornerstone for inflammation and immune modulation studies.
-
Rotigotine Hydrochloride: Precision Dopamine D2/D3 Agonist W
2026-04-20
Rotigotine hydrochloride delivers precise dopaminergic modulation for advanced Parkinson's disease and neurodegeneration models. This guide focuses on optimized protocols, experimental troubleshooting, and translational insights, leveraging APExBIO's rigorously characterized product.
-
Thioguanine: Mechanism, Evidence & Protocols for Oncology an
2026-04-19
Thioguanine (6-thioguanine) is a validated thiopurine immunosuppressant with robust antitumor and antiviral activities. Its primary targets are HGPRT and DNMT1, leading to potent inhibition of DNA synthesis and epigenetic modulation. Atomic evidence supports its efficacy in cancer and EV71 virus models.
-
ATM Inhibition and Fenofibrate Synergy in Ovarian Cancer Cel
2026-04-18
This study demonstrates that inhibiting the DNA repair kinase ATM, when combined with the metabolic modulator fenofibrate, synergistically induces senescence in high grade serous ovarian cancer (HGSOC) cells with intact homologous recombination. The findings identify a promising alternative therapeutic strategy for patients with HR-proficient HGSOC, expanding potential treatment options beyond DNA repair-targeted therapies.
-
TQB3720 Induces Ferroptosis in Prostate Cancer via AR/GPX4 A
2026-04-17
The reference study demonstrates that the second-generation androgen receptor antagonist TQB3720 suppresses prostate cancer growth by promoting ferroptosis through disruption of AR/SP1-mediated GPX4 transcription. This mechanistic insight offers a new therapeutic avenue for targeting resistant prostate cancer phenotypes and illustrates the importance of modulating redox and lipid peroxidation pathways.
-
Dual-Action Kinase Inhibitors Modulate p38α Dephosphorylatio
2026-04-16
The reference study demonstrates that certain p38 MAP kinase inhibitors not only block kinase activity but also accelerate dephosphorylation of the activation loop by phosphatase WIP1. This dual-action mechanism, revealed through structural and biochemical analyses, offers a new strategy for enhancing specificity and potency in targeting p38α, with significant implications for inflammatory disease research.
-
Chloroquine (BA1002): Technical Guide for Laboratory Researc
2026-04-15
Chloroquine (N4-(7-chloroquinolin-4-yl)-N1,N1-diethylpentane-1,4-diamine) is a well-characterized anti-inflammatory agent used in malaria and rheumatoid arthritis research, as well as in studies targeting autophagy and Toll-like receptor pathways. This article provides practical, evidence-based protocols and troubleshooting guidance for researchers using APExBIO Chloroquine (SKU BA1002), while clarifying boundaries where its use is not recommended or unsupported.
-
SB 431542 as a Precision Tool for TGF-β/SMAD Pathway Dissect
2026-04-14
Explore the scientific rigor and unique selectivity of SB 431542, a potent ALK5 inhibitor, in unraveling TGF-β/SMAD pathway biology. This article delivers protocol-level guidance and integrates new findings on smooth muscle cell proliferation and immunomodulation.
-
Palomid 529 (P529) in Cancer Research: Protocols & Best Use
2026-04-13
Palomid 529 (P529) is a dual mTORC1/mTORC2 inhibitor that advances oncology research by robustly blocking PI3K/Akt/mTOR signaling, inhibiting tumor angiogenesis, and potentiating radiotherapy. This article decodes proven workflows, troubleshooting tactics, and actionable insights for using P529 in both cancer and neural stem cell studies, translating cutting-edge research into bench-ready protocols.
-
D-Luciferin Sodium Salt: Precision Bioluminescence for Next-
2026-04-13
Discover how D-Luciferin sodium salt enables precise ATP-dependent bioluminescence assays for advanced cell viability and metabolism monitoring. This article uniquely bridges technical assay optimization with translational immunotherapy breakthroughs.
-
Sildenafil Citrate: A Selective cGMP-Specific PDE5 Inhibitor
2026-04-12
Sildenafil Citrate is a potent, selective cGMP-specific phosphodiesterase type 5 inhibitor with an IC50 of 3.6 nM, widely used in vascular and proteoform-specific research. Its efficacy in modulating smooth muscle relaxation and apoptosis via cGMP signaling is supported by robust mechanistic and proteomics evidence. APExBIO supplies a highly characterized form suitable for advanced workflows.